ROR2 is reported to have oncogenic properties in other tumour types such as oral cancer [12], renal cancer [13] and osteosarcoma [14]; it is frequently overexpressed in these tumours, and its suppression in renal cancer cells inhibits cell migration and growth in orthotopic xenograft models [13]. Here, ROR2 is linked to osteosarcoma.